From the Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia (CDR); Texas Retina Associates, Arlington, Texas (DGC); Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA (DVD); NJ Retina, New Brunswick, NJ (HFF); Rutgers UMDNJ Department of Ophthalmology, New Brunswick, NJ (HFF); Pepose Vision Institute, Chesterfield, MO (NMH); Gavin Herbert Eye Institute, University of California, Irvine, CA (BDK); Medical Center Ophthalmology Associates, San Antonio, TX (MAS); Cole Eye Institute, Cleveland (RPS).
This study was sponsored by Allergan plc, Dublin, and conducted by Endpoint Outcomes, Boston, MA. The study sponsor had the opportunity to review the manuscript but could not make changes in the manuscript; the content of the manuscript was fully controlled by and approved by the authors.
The authors report no proprietary interests in the products described in the article. Dr. Regillo is a consultant for Alcon, Allergan, Bayer, Genentech, Iconic, and Novartis and has received research grant support from Accucela, Alcon, Alimera, Allergan, Bayer, Genentech, GSK, Iconic, Novartis, Ophthotech, and Regeneron. Dr. Callanan is a consultant for AbbVie, Alcon, Allergan, Allgenesis, Forsight, Graybug, Regeneron, pSivida, and Santen. Dr. Do is a consultant for Allergan, Genentech, and Santen and has received research funding from Allergan, Genentech, Regeneron, and Santen. Dr. Fine is a consultant for Alimera, Allergan, Genentech, and Regeneron and has received research grant support from Alcon, Alimera, Allergan, Genentech, GSK, and Regeneron. Dr. Holekamp is a consultant for Alimera Sciences, Allergan, Genentech, Katalyst, Novartis, and Regeneron and has received research grant support from Alimera Sciences, Allergan, Genentech, and Opthotech. Dr. Kuppermann is a consultant for Acucela, Aerpio, Alcon, Alimera, Allegro, Allergan, Ampio, Catalyst, Dose, Eleven Biotherapeutics, Genentech, Glaukos, Lumenis, Novartis, Ophthotech, Regeneron, and ThromboGenics and has received research grant support from Alcon, Alimera, Allegro, Allergan, Apellis, Genentech, GSK, J-Cyte, Neurotech, Ohr, Ophthotech, Regeneron, and ThromboGenics. Dr. Singer is a consultant for Aerpio, Alimera, Allergan, Ampio, Genentech, and Santen and has received research grant support from Acucela, Aerpio, Alcon, Alimera, Allergan, Ampio, Genentech, Ophthotech, and Regeneron. Dr. Singh is a consultant for Alcon, Genentech, Optos, Regeneron, Shire, and Zeiss and has received research grant support from Alcon, Apellis, Ophthotech, Regeneron, and Roche.
The authors thank Chris Evans, Nate Johnson, and Nicole Lyn of Endpoint Outcomes for their contributions to the study. Writing and editorial assistance was provided to the authors by Kate Ivins, PhD, of Evidence Scientific Solutions, Philadelphia, and funded by Allergan plc. All authors met the ICMJE authorship criteria. Neither honoraria nor payments were made for authorship.
Address correspondence to Carl D. Regillo, MD, Wills Eye Hospital, 840 Walnut Street, Suite 1020, Philadelphia, PA 19107; email:
cregillo@midatlanticretina.com.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0). This license allows users to copy and distribute, to remix, transform, and build upon the article, for any purpose, even commercially, provided the author is attributed and is not represented as endorsing the use made of the work.